Bhagwan Marine Limited (ASX: BWN) has emerged as Australia’s largest ASX-listed marine services provider, following its IPO in July 2024. Since debuting on the market, the Company has delivered on its strategy of operational excellence, sustainable growth, and diversification across multiple marine sectors. With a 23% increase in share price from the IPO price of $0.50 to $0.63 in June 2025, BWN’s strong market showing is underpinned by solid financial and operational perform

Cuscal Limited (ASX: CCL) is a name that has quietly underpinned the digital payments infrastructure of Australia for decades. After officially listing on the ASX on 25 November 2024, Cuscal is now navigating the next chapter of its 60-year journey — building on its foundation as one of the nation’s leading independent B2B payments and data service providers.

This is our second Samso Radar - Weekly Review, and this week we are looking at the Health Care sector on the ASX. The timing may be now for investors to take notice and understand the ASX Healthcare sector as some signs are showing that a counter-cyclical opportunity may be in play in 2025. Timing is the key and this Samso Radar Weekly Review may be the beginning the understanding process.

Fulcrum Lithium Ltd (ASX: FUL) has entered the ASX stage with ambitions as large as its Nevada lithium portfolio. Since its IPO in November 2024, Fulcrum has maintained a sharp operational pace, demonstrating early exploration success and strategic clarity across three key lithium projects—Alkali Flats, Fairway, and Summit

Investing in mineral exploration stocks on the ASX can offer exciting opportunities, but it also carries unique challenges. With over 30 years of experience as a geologist in the industry, I have witnessed both the highs and lows of the mineral resource market. I have seen proejcts go from a Urnaium project to being a Phosphate project in 6 months and Nickel to Gold or vice versa, in a simialr time frame. Knowing the complexities in this sector is vital for making informed i

When it comes to spotting undervalued potential in biotech, I often look for companies that are not only developing novel technologies but also demonstrating clear paths to commercialisation. This month, three small-cap names on the ASX have really caught my attention: Memphasys Limited (ASX: MEM), Control Bionics (ASX: CBL), and dorsaVi Ltd (ASX: DVL). Each is on a very different mission, but all three are making measurable progress—and investors are starting to notice.

nvesting in small-cap stories on the ASX (Australian Stock Exchagne) in 2025 can seem overwhelming, especially for beginners. With the abundance of information available, it is crucial to know how to sift through it effectively to make informed decisions. As I have been in this industry for over 30 years and as an investor prior to the 1987 stockmarket crash, this blog will just outline some of my own experience and insights as to what has wroked for me over those years.

The narrative around critical minerals is no longer just a story of energy transition. It has become a complex intersection of economics, security, diplomacy, and market psychology. At first, it was about rare earths and lithium. Now the ripples have spread across copper, gold, iron ore, antimony, and more.